Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Naval Daver MD

Naval Daver MD

Associate Professor, Leukemia Department, MD Anderson Cancer Center, Houston, TX

Dr Naval Daver is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He completed his medical school from Grant Medical College and Sir J J group of Hospitals, Mumbai followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine. He is a clinical investigator with a focus on molecular and immune therapies in AML and Myelofibrosis and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint and vaccine based approaches, as well as targeted and apoptotic therapies in AML and is leading a number of these trials at MDACC. Dr Daver has published >200 peer-reviewed manuscripts and is on the editorial board of numerous hematology specific journals. He has also authored numerous abstracts at national and international conferences.


Dr. Daver’s List of Financial Disclosures: Pfizer, Otsuka, Novartis, BMS, Incyte, Sunesis, Karyopharm, Jazz, Daichi-Sankyo, Abbvie, Glycomimetics, Servier, Genentech, Covance, Immunogen, NOHLA Therapeutics, Agios

Research Funding: Pfizer, BMS, Novartis, Daiichi-Sankyo, Karyopharm, Incyte, Abbvie, Sunesis, Servier, Genentech, NOHLA, Glycomimetics, Immunogen

Advisory/Consulting: Pfizer, Novartis, BMS, Otsuka, Celgene, Incyte, Jazz, Karyopharm, Sunesis, Immunogen, Abbvie,Astellas, Daiichi-Sankyo, Agios

Dr. Daver’s List of Financial Disclosures

Honararia: BMS, Jazz, Novartis, Incyte, Otsuka, Immunogen, Pfizer, Astellas, Abbvie